SSB-4

SSB-4, a Non-Antibody Inhibitor Blocks Binding of SARS-CoV-2  to ACE2

SSB-4 is a non-antibody biologics specifically engineered for blocking the infection of the coronavirus SARS-CoV-2 by abolishing interaction between viral spike protein with ACE2 which is the gateway of virus entry into human cells. Our candidate molecule contains all human sequence, exhibits a single digit nanomolar affinity, and is highly efficacious in blocking pseudovirus infection on ACE2 expression cells.

If you are interested in SSB-4 project, please contact us.

Research Projects

  • PRIM

    Recombinant protein as a Pan Fc Receptor Interacting molecule.

    Learn More 

  • PD-L1 Decoy

    Cancer treatment via symbiosis with tumor tissues through slowing down the progression of cancer-triggered cachexia.

    Learn More 

  • Abmining

    Massive antibody mining, an unique platform for accelerating R&D timelines of therapeutic antibodies.

    Learn More 

  • SSB-4

    A Non-Antibody Biologics engineered for Blocking of SARS-CoV-2 Binding to ACE2.

    Learn More